Hematopoietic adverse events associated with PARP inhibitors: A FAERS database study
PARP inhibitors vary in ADR incidence and duration, necessitating personalized treatment plans for optimized safety and rational use.
Authors
- Qindai Shuai
- Li Wang (ORCID: https://orcid.org/0000-0003-4643-0359)
- Gen Li (ORCID: https://orcid.org/0000-0002-6862-5547)
- Li Chen (ORCID: https://orcid.org/0000-0002-5771-9740)
- Jia Chen (ORCID: https://orcid.org/0000-0002-6933-408X)
- Xuefei Bai
Institutions
- China Pharmaceutical University (CN)
- Tianjin University (CN)
- University of the Basque Country (ES)
- Sichuan University (CN)
- West China Second University Hospital of Sichuan University (CN)
- Maternal and Child Health Hospital of Sichuan Province (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1080/14740338.2024.2443781
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00